

Alessia Campagna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9854601/publications.pdf>

Version: 2024-02-01

14
papers

205
citations

1684188

5
h-index

1474206

9
g-index

14
all docs

14
docs citations

14
times ranked

356
citing authors

#	ARTICLE	IF	CITATIONS
1	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. Journal of Clinical Medicine, 2022, 11, 2596.	2.4	0
2	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1223-1233.	1.6	127
3	Clinical relevance of clonal hematopoiesis in persons aged ≥80 years. Blood, 2021, 138, 2093-2105.	1.4	37
4	Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 268-271.	2.4	3
5	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematological Oncology, 2020, 38, 189-196.	1.7	6
6	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. Leukemia and Lymphoma, 2020, 61, 3476-3483.	1.3	2
7	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. Expert Opinion on Drug Safety, 2020, 19, 187-204.	2.4	5
8	Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. Leukemia Research, 2019, 76, 65-69.	0.8	8
9	A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. BMC Cancer, 2019, 19, 50.	2.6	15
10	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. Blood, 2019, 134, 3010-3010.	1.4	0
11	DEVEC metronomic schedule for aggressive B and T-cell lymphomas.. Journal of Clinical Oncology, 2018, 36, 7563-7563.	1.6	0
12	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. Blood, 2018, 132, 5516-5516.	1.4	0
13	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. Blood, 2016, 128, 5544-5544.	1.4	1
14	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). Blood, 2016, 128, 5465-5465.	1.4	1